Orano Med Doubles Clinical Supply Capacity at Plano Facility

• Orano Med has expanded its Plano, Texas R&D centre by 1,000 m² following a $5 million investment.

• The site now doubles GMP production capacity and houses both internal research and preclinical studies for lead-212-based therapies.

Orano Med, a subsidiary of the Orano Group and a developer of vector-guided internal radiotherapy (VIR), has announced the completion of a major expansion to its research and development centre in Plano, Texas. The expansion adds around 1,000 m² to the site, including 465 m² of new laboratory space and 511 m² of office space.

The $5 million investment supports the company’s aim to fast-track the development of its pipeline of lead-212-based drug candidates. The upgraded site, now named the Drug Development and Preclinical Unit (DDPU) – Centre George de Hevesy, also doubles the site’s GMP manufacturing capacity for early-stage clinical trials.

Julien Torgue, Scientific Director of Orano Med, said: “The expansion of our R&D center strengthens our capacity to develop lead-212-based vectorized internal radiotherapies, providing our teams with the resources needed to advance our portfolio of molecules to clinical trials.”

The Plano facility brings together Orano Med’s R&D team and its subsidiary Macrocyclics, which focuses on chelating agents. The fully integrated site supports internal and partnered projects, handling preclinical, in vivo, and CMC studies to ensure a seamless transition to the clinic.

Arnaud Lesegretain, Chairman and CEO, noted that the Plano site has played a central role since the company’s founding: “It strengthens our high-level R&D resources in the United States and enhances our ability to develop innovative targeted alpha therapies.”